What type of study is this?

This is a Literature Review study.

September 22, 2025Canadian Hematology TodayOpen Access

Cellular Therapy and Follicular Lymphoma: Where Do We Stand in 2025?

View Full Paper

Ask AI

Bookmark

Authors

HEHadel El-HaddadUniversity of British Columbia HCHannah CherniawskyBC Cancer Agency

Discussion

Member takes

Implication

This review evaluates T-cell redirecting therapies and their impact on overall survival in follicular lymphoma patients, highlighting treatment challenges.

Key Points

Patients with low-risk follicular lymphoma experience over 20 years of overall survival despite inferior outcomes in those with adverse features.
Progression of disease within 24 months of treatment and high FLIPI scores significantly lower survival rates for patients with follicular lymphoma.
Standardized second-line treatment for follicular lymphoma remains inconsistent due to variations in patient fitness and medication access.
The overall response duration declines with each subsequent line of therapy, underscoring the challenges in managing follicular lymphoma.

Cite This Study

El-Haddad et al. (2025) studied this question.

synapsesocial.com/papers/68d46fdc31b076d99fa6a56e https://doi.org/10.58931/cht.2025.4271

View Full Paper

Ask AI

Bookmark

Implication

This review evaluates T-cell redirecting therapies and their impact on overall survival in follicular lymphoma patients, highlighting treatment challenges.

Cellular Therapy and Follicular Lymphoma: Where Do We Stand in 2025?

Discussion

Member takes

Implication

Key Points

Cite This Study

Cellular Therapy and Follicular Lymphoma: Where Do We Stand in 2025?

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider